The clinical question remains as to whether stress is a trigger—or at least an exacerbating factor—in psoriasis and if so, how this should influence treatment approaches.
The FDA has approved the supplemental Biologics License Application (sBLA) for Taltz (ixekizumab: Lilly) injection for the treatment of pediatric patients aged ≥6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The role of mechanoinflammation in the pathogenesis of psoriatic disease and the presence of entheseal lesions as predictors of the onset of clinical joint disease gain support in a new study.
A significant association between indoor tanning frequency and a diagnosis of psoriasis was noted; physicians should caution their patients with psoriasis against the use of non-medical indoor tanning as a therapy.
A novel trial examining dose reduction strategies for biologic agents for the treatment of psoriasis found that successful dose tapering was possible in more than half of patients, which can have an effect on healthcare expenditures.
A Western diet can, in as little as 4 weeks, result in clinically and molecularly significant proinflammatory changes in the skin, underscoring the relationship between dietary components and skin disease.
